I'm the bad guy ha?? (Directed to all, except you Bobo).

New Post Public Reply Private Reply Replies (1) Message Board
La19 BoBo #3544
I'm the bad guy ha?? (Directed to all, except you Bobo). I'm not right Bobo, the findings are facts. Childish is Mr. Ceo paying himself 400k, and buying 2yrg and not visiting the facility nor sending a representative to see what exactly we were buying, in addition, not even reading the fckng buying agreement, unless and incompetent, time for the board to acquire a vote and have him hit the exit door.

Or do we even have a vote?? My money is down 97% is so is many of us here, don't be shy to speak it and question the practices of what our CEO has been doing since the first phases. I know some here who are in the same boat. Others who are trying to take legal action and have wrote Martin, and his responded with no avail. I've seen those emails, folks who are down from 45k to 130k. Where are all the Pro longs NOW, they're gone, they flipped the stock and waited on the 1st Q to see China Revs, and bailed out, dumped it and moved on. No of them played the long card, they played the smart card, but some of us believe in this company, like I did. Now I'm a bag holder, all you criticizing me, could be insiders trying to discredit me, and taking from what is really going on. What that is, if you ask:

3.9 Million dollars into professional fees, god damn that's a whole lot of paying out for a company making only 60k in gross revenue. Have Martin answer that question, ha? This quarter alone $500k + in those fees?? Who is getting this money, who??

Per Malone "ex-accountant firm", which Martin was praising so bad when we attained them. Malone will bring reputable and extensive expirience with our Chinese auditings, because Malone has extensive expirience. Malone read the filings and told Marin and management, these numbers are exaggerated. Here's the article; but I'm he bad guy ha?? I guess you guys are waiting on the 50 Million from
Tanke, tankes is a pump and dump stock. Go hit stock promoters dot com, look at the pump that occurred from March to June if I'm correct with the months, but it started at .10 then the mail-outs started happening and the pumping game took it to .50 cents, then it got diluted to nothing. Anything associated with Tanke was not good, many PM'd me to bail out once Martin issued like 2 PRs in regards to Tanke's partnership. I didn't listening, beliving Martins reputation. Do some research on some of the members of Evotech. See how many company's have been started and burned. Supported this crap like a good soldier, blinded by lies and deceitful actions.
When they use to report every week the O/S I was calm and believes they're were nothing to hide, then it all changed to monthly, and that's when the dilution started happening. We were at .05s guys, five cents. We dropped to .01 pretty fast, I said nothing to worry about, just some support lost, no biggie, good co, let me buy some more. I did! Look at us now man, were looking like a typical penny stock, Martin let us down, we even lost QB status, and now were a plain Pinky. I know you fckng insiders are here pumping this BS, but I will keep posting the truth, my posting a consist on the facts your CEO put Out, now is time for you to eat it too, don't like it, well, hell, it's only the facts management issued. Where in management now, where is our public relations? A word from Malone;

Dear Mr. Nielson:

This is a follow up to our resignation email dated and effective March 1, 2014 wherein we resigned as the independent registered public accountants for E-Waste Systems, Inc. (“E-Waste”). The reason for the resignation stems from our disagreement with E-waste’s management concerning the accounting treatment of certain transactions involving China based companies.

It was our understanding that E-waste entered into certain “lease” agreements with several Chinese companies in 2013. Under these “lease” agreements, E-waste apparently accounted for gross revenue[ and expenses of these China based operations during 2013. THAT'S NOT TOO CONVINCING HOW HE WORDED IT, MHO.

Based on the documents we have reviewed and interviews we have conducted so far, it does not appear that there is substance related to the “lease” agreements to warrant E-waste to account for gross revenue and expenses for these China based operations.
NO GROSS REVENUE NOR EXPENSES, I'M WITH MALONE. MARTIN ALSO PRAISED MALONE WHEN HE HIRED HIM, SAID HE WAS CONFIDENT ON MALONE'S ACCOUNTING TEAM, AND THEY WERE EXPERTS IN CHINESE AND US ACCOUNTING FINANCIALS.

Our conclusion was reached based on our review of the ”lease” agreements and an interview with E-Waste’s key management team member that has closed every transaction in China and maintained management of the business units.

We believe that the overstated revenue and expenses could have a material impact on E-Waste’s consolidated financial statements. BINGO, THE PUNCH LINE...

This disagreement should be disclosed in the Item 4.01 Change of auditor Form 8-K filing which is due four business days from our email resignation.

Very truly yours,



/s/ MaloneBailey, LLP
MaloneBailey, LLP

E-Waste Systems, Inc. (EWSI) Stock Research Links

EWSI Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 43

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 47

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 38

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 44

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 38

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 35

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into AppLovin Corporation's Alleged Fraud

Updated Category News Views 386

Investigation into AppLovin Corporation In recent news, a substantial class action lawsuit has emerged against AppLovin Corporation (NASDAQ: APP). This national law firm, known for advocating for investors, aims to hold the company accountable for alleged securities law violations. Understanding the Class Action Lawsuit This lawsuit pertains to any individuals or entities...

Continue Reading
Safe Harbor Financial Expands Support for Cannabis Operators

Updated Category News Views 33

Safe Harbor Financial Takes Bold Step in Cannabis Financing In a remarkable move, Safe Harbor Financial has successfully arranged a secured credit facility valued at $1.07 million. This milestone supports a cannabis operator, marking a significant step in bolstering financial services within the cannabis industry. With their expertise in facilitating innovative financial...

Continue Reading
Nidec Corporation Faces Securities Investigation: Key Insights

Updated Category News Views 224

Understanding Nidec Corporation's Current Challenges Nidec Corporation is undergoing scrutiny due to serious allegations in its business practices. This Japanese manufacturer, known for its electronic components, faces potential claims of issuing misleading information to its investors. Recent developments have raised questions about its transparency and accountability in...

Continue Reading
Understanding HCI Group's Short Interest Trends and Insights

Updated Category News Views 126

An Overview of HCI Group's Short Interest HCI Group's short interest has sparked interest among traders and investors alike, showing a recent increase of 7.38% from the previous report. This shift indicates that there are currently around 404 thousand shares sold short, comprising 4.95% of the company’s total tradable shares. Observing the trading volume, it has been...

Continue Reading
Fresenius Kabi Introduces New Epinephrine Injection for Patients

Updated Category News Views 151

Fresenius Kabi Launches Epinephrine Injection, USP Fresenius Kabi, a proud branch of the Fresenius organization, has taken a significant step in enhancing its pharmaceutical portfolio in the United States by making available Epinephrine Injection, USP. This launch positions Fresenius Kabi at the forefront as it becomes the first company to offer a generic 1mg/1mL vial of...

Continue Reading